About the journal
Current Cancer Drug Targets is a journal published by Bentham Science Publishers in Netherlands. It is listed in MEDLINE and PUBMED according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Bentham Science Publishers
- ISSN
- 1568-0096 · 1873-5576
- Country
- Netherlands
- Access
- Not open access / not declared
- Official website
- http://www.benthamscience.com/ccdt/index.htm
Index listings
- MEDLINE · 2001-01-01
- PUBMED · 2010-12-15
- Indexing
- MEDLINE · PUBMED
- APC
- —
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 102 days received→accepted — computed from PubMed (n=96)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
2103
Last recorded publication year
2026
h-index
114
i10-index
1201
From OpenAlex open data (CC0).
Editorial & policy5
- Observed digital preservation (Keepers registry)— snapshot 2026-09-21
- Portico
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 60%
- ORCID iDs in current deposits
- 37%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101094211
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer Mechanisms and Therapy
- Cancer Mechanisms and Therapy
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Cancer, Lipids, and Metabolism
Show all subjects (50)
- Cancer Immunotherapy and Biomarkers
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Histone Deacetylase Inhibitors Research
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Cancer-related Molecular Pathways
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- MicroRNA in disease regulation
- Diverse Scientific and Economic Studies
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- Diverse Scientific and Economic Studies
- HER2/EGFR in Cancer Research
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Computational Drug Discovery Methods
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- Cancer therapeutics and mechanisms
- Computational Drug Discovery Methods
- Cancer-related molecular mechanisms research
- Cancer-related molecular mechanisms research
- Nanoparticle-Based Drug Delivery
- Nanoparticle-Based Drug Delivery
- Immunotherapy and Immune Responses
- 14-3-3 protein interactions
- Immunotherapy and Immune Responses
- 14-3-3 protein interactions
- Synthesis and biological activity
- Synthesis and biological activity
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ